Maxcyte (MXCT) Free Cash Flow (2020 - 2026)

Maxcyte has reported Free Cash Flow over the past 6 years, most recently at -$4.4 million for Q4 2025.

  • Quarterly Free Cash Flow rose 53.08% to -$4.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$36.2 million through Dec 2025, down 23.64% year-over-year, with the annual reading at -$36.2 million for FY2025, 23.64% down from the prior year.
  • Free Cash Flow was -$4.4 million for Q4 2025 at Maxcyte, up from -$7.4 million in the prior quarter.
  • Over five years, Free Cash Flow peaked at $9.8 million in Q4 2022 and troughed at -$15.1 million in Q1 2025.
  • The 5-year median for Free Cash Flow is -$5.8 million (2021), against an average of -$5.7 million.
  • The largest YoY upside for Free Cash Flow was 991.74% in 2022 against a maximum downside of 2302.67% in 2022.
  • A 5-year view of Free Cash Flow shows it stood at -$1.1 million in 2021, then soared by 991.74% to $9.8 million in 2022, then tumbled by 92.86% to $702000.0 in 2023, then crashed by 1444.3% to -$9.4 million in 2024, then soared by 53.08% to -$4.4 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Free Cash Flow are -$4.4 million (Q4 2025), -$7.4 million (Q3 2025), and -$9.3 million (Q2 2025).